Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy

Insmed Inc. (NASDAQ:INSM) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. On January 23, Roth/MKM began coverage of Insmed Inc. (NASDAQ:INSM) with a Buy rating and a $212 price target. The firm pointed to Insmed’s solid position for further upside in 2026, with predictions that the company’s Brinsupri medication will continue to exceed market expectations.

Moreover, the firm assigned a 75% probability of success to the company’s Phase 3 ENCORE trial, with results expected in March or April. A favorable outcome might generate roughly $1.3 billion in frontline Arikayce sales.

Although Roth/MKM views the brensocatib CEDAR trial for hidradenitis suppurativa as risky, the firm believes the recent CRSsNP setback has reset investor expectations ahead of the second-quarter 2026 report, boosting the stock’s risk/reward outlook.

Insmed Inc. (NASDAQ:INSM) is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. The company’s most advanced programs focus on pulmonary and inflammatory conditions.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.